hot dry skin; previous dose of covid-19 vaccine astra zeneca and third dose of comirnaty; previous dose of covid-19 vaccine astra zeneca and third dose of comirnaty; this is a spontaneous report received from a contactable reporter(s) (consumer or other non hcp) from the regulatory authority. regulatory number: gb-mhra-webcovid-202202161313505580-qsnsw. other case identifier(s): gb-mhra-adr 26609905. a 56 year-old female patient received bnt162b2 (comirnaty), administered in arm right, administration date 09feb2022 (batch/lot number: unknown) as dose 3 (booster), single for covid-19 immunisation. the patient's relevant medical history and concomitant medications were not reported. vaccination history included: covid-19 vaccine astrazeneca (dose number unknown, single, lot number: not reported), for covid-19 immunisation; covid-19 vaccine (dose number unknown; manufacturer unknown), for covid-19 immunisation. the following information was reported: off label use (medically significant), interchange of vaccine products (medically significant) all with onset 09feb2022, outcome "unknown" and all described as "previous dose of covid-19 vaccine astra zeneca and third dose of comirnaty "; dry skin (medically significant) with onset 12feb2022, outcome "not recovered", described as "hot dry skin". the patient underwent the following laboratory tests and procedures: sars-cov-2 test: no - negative covid-19 test. clinical course: patient has not had symptoms associated with covid-19. arm looks like sunburn, hot to touch the vaccine was admitted into the right arm and reaction is further away from the vaccine site. patient has not tested positive for covid-19 since having the vaccine. patient is not enrolled in clinical trial. this report did not relate to possible inflammation of the heart (myocarditis or pericarditis. no follow-up attempts are possible; information about lot/batch number cannot be obtained. no further information is expected

test name: covid-19 virus test; result unstructured data: test result:no - negative covid-19 test

na

na